Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
(2018).
Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens..
Leuk Lymphoma. 58(8), 1832-1839.
(2017).
(2016).
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib..
Clin Cancer Res. 15(23), 7153-60.
(2009). Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition..
J Clin Endocrinol Metab. 92(12), 4845-52.
(2007). The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro..
Invest Ophthalmol Vis Sci. 48(10), 4706-19.
(2007). Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro..
J Clin Endocrinol Metab. 91(10), 4013-21.
(2006). Successful treatment of lymph node extramedullary plasmacytoma with bortezomib..
Ann Hematol. 85(3), 188-90.
(2006).